These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25999445)

  • 1. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
    Rashidi A; Oak E; Bartlett NL
    Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.
    Cha SI; Choi KJ; Shin KM; Lim J; Yoo SS; Lee J; Lee SY; Kim CH; Park JY
    Respiration; 2013; 85(2):175. PubMed ID: 23234874
    [No Abstract]   [Full Text] [Related]  

  • 3. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.
    Tuccori M; Focosi D; Blandizzi C; Pelosini M; Montagnani S; Maggi F; Pistello M; Antonioli L; Fornai M; Pepe P; Rossi G; Petrini M
    Oncologist; 2010; 15(11):1214-9. PubMed ID: 21041380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subcutaneous Rituximab is effective and safe].
    Häckel A
    Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
    [No Abstract]   [Full Text] [Related]  

  • 5. No studies have shown improved overall survival with maintenance therapy.
    Ujjani C
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541, 544-6. PubMed ID: 25356580
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment.
    Sano Y; Nakano Y; Omoto M; Takao M; Ikeda E; Oga A; Nakamichi K; Saijo M; Maoka T; Sano H; Kawai M; Kanda T
    Intern Med; 2015; 54(8):965-70. PubMed ID: 25876582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular adverse events complicating the administration of rituximab: report of two cases.
    Passalia C; Minetto P; Arboscello E; Balleari E; Bellodi A; Del Corso L; Molinari E; Ponassi I; Oneto C; Sicbaldi V; Ghio R
    Tumori; 2013; 99(6):288e-92e. PubMed ID: 24503806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
    Dawson K
    J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
    Yang JD; Girotra M; Vaid A; Duarte-Rojo A
    J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
    Laurenti L; De Padua L; Battendieri R; Tarnani M; Sica S; Blasi MA; Savino G; Leone G
    Leuk Res; 2011 May; 35(5):682-4. PubMed ID: 21334067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012.
    Kassab S; Saghi T; Boyer A; Lafon ME; Gruson D; Lina B; Fleury H; Schuffenecker I
    Emerg Infect Dis; 2013 Aug; 19(8):1345-7. PubMed ID: 23880543
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: report of two rare complications and review of the literature.
    Urun Y; Dincol D; Kumbasar OO
    J BUON; 2012; 17(3):602-3. PubMed ID: 23033310
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
    Liapis K; Harhalakis N; Stefanou G; Apostolidis J
    J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of acute adverse events from rapid rituximab infusion.
    Lang DS; Keefe DM; Schultz T; Pearson A
    Support Care Cancer; 2013 Aug; 21(8):2315-20. PubMed ID: 23525938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
    Hegele V; Stoll P; Wüst D; Ehrenbrink G; Grazziotin LR; Caregnato JP; Lindenmeyer LP
    Int J Clin Pharm; 2013 Aug; 35(4):513-9. PubMed ID: 23737385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
    Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
    Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of plasma exchange on rituximab pharmacokinetics.
    Azzopardi N; François M; Laurent E; Paintaud G; Birmelé B
    Br J Clin Pharmacol; 2013 Sep; 76(3):486-8. PubMed ID: 23713740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.